| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
|
Purity: ≥98%
SBE-β-CD, also named as Sulfobutylether beta-cyclodextrin or Captisol, is a highly water-soluble anionic derivative of cyclodextrin that is widely used as an excipient or a formulating agent to increase the solubility of poorly soluble drugs. The sodium sulfonate salt of it is separated from the lipophilic cavity by a butyl ether spacer moiety, namely the sulfobutylether (SBE). SBE-β-CD can form non-covalent inclusion complexes with drug molecules, by so doing, it can improve drug stability, solubility and safety, reduce toxicity, cover up bad smell, and control drug release rate. As an excipient, SBE-β-CD has been used in various formulation including injection, oral, nasal and eye medication. Modification of the structure by charged functional groups can improve the binding affinity of cyclodextrins for oppositely charged guests, therefore it has a specific affinity for drugs containing nitrogen atoms.
| Targets |
excipient and/or formulating agent
|
||
|---|---|---|---|
| ln Vitro |
SBE-β-CD, a negatively charged cyclic hydrophilic oligosaccharide in aqueous media, is β-CD that has been chemically modified. SBE7-β-CD shows robust solubilizing effects over a wide concentration range, while β-CD is only effective as a solubilizing agent at low doses [1].
|
||
| ln Vivo |
How to prepare 20% SBE-β-CD in Normal Saline? Guidelines (This is our suggested protocol; it should be adjusted to suit your particular requirements; it is merely meant to serve as a guide).
1). A clear 0.9% saline solution can be made by dissolving 0.9 g of NaCl in 100 mL of distilled water. 2). Weigh 2 grams of dry SBE-β-CD. 3). To make 10 mL of a 20% (w/v) solution, dissolve 2 g of SBE-β-CD in 0.9% saline. These might need to be heated (for roughly 30 minutes at 37°C) or sonicated (20–40 kHz, 30 seconds, repeat three times). Before using, dissolve any precipitates that are seen by heating to 37°C and vortexing. |
||
| Animal Protocol |
|
||
| References |
|
| Molecular Formula |
C50H84NA2O41S2
|
|
|---|---|---|
| Molecular Weight |
1451.3
|
|
| Exact Mass |
1450.372
|
|
| CAS # |
182410-00-0
|
|
| Related CAS # |
|
|
| PubChem CID |
135393453
|
|
| Appearance |
White to off-white solid powder
|
|
| Hydrogen Bond Donor Count |
19
|
|
| Hydrogen Bond Acceptor Count |
41
|
|
| Rotatable Bond Count |
19
|
|
| Heavy Atom Count |
95
|
|
| Complexity |
2500
|
|
| Defined Atom Stereocenter Count |
35
|
|
| SMILES |
[R]O[C@@H]1[C@H](O[R])[C@H](O[C@@H]2[C@H](O[R])C(O[R])[C@H](O3)[C@@H](CO[R])O2)[C@@H](CO[R])O[C@@H]1O[C@H]4[C@H](O[R])[C@@H](O[R])[C@@H](O[C@H]5[C@H](O[R])[C@@H](O[R])[C@@H](O[C@@H]6C(O[R])[C@H](O[R])[C@H](O[C@@H]7[C@@H](O[R])[C@H](O[R])[C@H](O[C@@H]8[C@@H](O[R])[C@H](O[R])[C@H]3O[C@H]8CO[R])O[C@H]7CO[R])O[C@H]6CO[R])O[C@@H]5CO[R])O[C@@H]4CO[R].[R= H 21-m or C4H8SO3-Na+ m , m=6.0-7.1]
|
|
| InChi Key |
RGQYVQYXCZODQW-XRONRANPSA-L
|
|
| InChi Code |
InChI=1S/C50H86O41S2.2Na/c51-9-16-36-23(57)29(63)45(78-16)86-38-18(11-53)80-47(31(65)25(38)59)88-40-20(13-55)82-49(33(67)27(40)61)90-42-22(15-76-5-1-3-7-92(70,71)72)84-50(43(35(42)69)77-6-2-4-8-93(73,74)75)91-41-21(14-56)83-48(34(68)28(41)62)89-39-19(12-54)81-46(32(66)26(39)60)87-37-17(10-52)79-44(85-36)30(64)24(37)58;;/h16-69H,1-15H2,(H,70,71,72)(H,73,74,75);;/q;2*+1/p-2/t16-,17-,18-,19+,20+,21+,22+,23-,24-,25-,26+,27+,28+,29-,30-,31-,32+,33+,34+,35-,36-,37-,38-,39+,40+,41+,42+,43+,44-,45-,46+,47-,48+,49+,50+;;/m0../s1
|
|
| Chemical Name |
beta-cyclodextrin sulfobutyl ether sodium salts;
[[(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18S,20S,21R,23S,25S,26R,28S,30S,31R,33R,35R,36R,37R,38S,39S,40S,41S,42S,43S,44R,45R,46S,47R,48R,49R)-36,37,38,39,40,41,42,43,44,45,46,48,49-tridecahydroxy-5,15,20,25,30,35-hexakis(hydroxymethyl)-47-(4-sulfonatobutoxy)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-10-yl]methoxy]butane-1-sulfonate |
|
| Synonyms |
Sodium sulfobutylether β-cyclodextrin; SBE-β CD; SBE-β-CD; SBE β-CD; SBE β CD; SBE-beta-CD; Sulfobutylether beta-cyclodextrin; Captisol; beta-cyclodextrin sulfobutyl ether sodium salts
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6890 mL | 3.4452 mL | 6.8904 mL | |
| 5 mM | 0.1378 mL | 0.6890 mL | 1.3781 mL | |
| 10 mM | 0.0689 mL | 0.3445 mL | 0.6890 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA